OncoResponse, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2016-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.oncoresponse.com
Clinical Trials
2
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
Phase 1
Recruiting
- Conditions
- CancerTumor, SolidMalignant NeoplasmMetastatic CancerAdvanced Solid TumorCutaneous MelanomaNon-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2023-10-19
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- OncoResponse, Inc.
- Target Recruit Count
- 168
- Registration Number
- NCT06090266
- Locations
- 🇺🇸
NEXT Austin, Austin, Texas, United States
🇺🇸NEXT Dallas, Irving, Texas, United States
🇺🇸NEXT Oncology, San Antonio, Texas, United States
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
Phase 1
Recruiting
- Conditions
- CancerHead and Neck Squamous Cell CarcinomaMetastatic CancerLeiomyosarcomaTumor, SolidNon Small Cell Lung CancerMalignant NeoplasmAdvanced Solid TumorMelanomaLiposarcoma
- Interventions
- First Posted Date
- 2021-10-26
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- OncoResponse, Inc.
- Target Recruit Count
- 172
- Registration Number
- NCT05094804
- Locations
- 🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸NEXT Austin, Austin, Texas, United States
🇺🇸NEXT Oncology, San Antonio, Texas, United States
News
No news found